<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23060" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyaluronidase</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Murray</surname>
            <given-names>Rachel L.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zafar Gondal</surname>
            <given-names>Anoosh</given-names>
          </name>
          <aff>Rawal Institute of Health Sciences</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rachel Murray declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anoosh Zafar Gondal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23060.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Hyaluronidase is an enzyme useful in facilitating the management of injectable medications. This activity reviews the indications, action, adverse effects, and contraindications for hyaluronidase as an important adjuvant therapy for patients requiring subcutaneous injections. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent to members of the interprofessional team in the care of patients with chronic injection therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of hyaluronidase.</p></list-item><list-item><p>Describe the potential adverse effects of hyaluronidase.</p></list-item><list-item><p>Review the appropriate monitoring and toxicity of hyaluronidase.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance hyaluronidase therapy and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23060&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23060">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23060.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Many patients with chronic diseases require injections&#x000a0;as part of their prolonged medical therapy. Hyaluronidase has been shown to enhance the&#x000a0;systemic delivery of injectable medications and provide better treatment outcomes for these patients.&#x000a0;Examples of current medications being using in combination with hyaluronidase&#x000a0;include, but are not limited to: insulin in diabetes, beta interferons in multiple sclerosis, biotherapeutics in rheumatoid arthritis, immunoglobulin replacement therapy in primary immunodeficiencies, and monoclonal antibodies in cancer treatment.<xref ref-type="bibr" rid="article-23060.r1">[1]</xref>&#x000a0;Hyaluronidase is currently&#x000a0;used for several other types of medical management as well.&#x000a0;</p>
        <p>
<bold>FDA Approved Indications</bold>
<xref ref-type="bibr" rid="article-23060.r1">[1]</xref>
<xref ref-type="bibr" rid="article-23060.r2">[2]</xref>
<xref ref-type="bibr" rid="article-23060.r3">[3]</xref>
<xref ref-type="bibr" rid="article-23060.r4">[4]</xref>
<xref ref-type="bibr" rid="article-23060.r5">[5]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Absorption and dispersion enhancer of injected drugs</p>
          </list-item>
          <list-item>
            <p>Subcutaneous fluid administration for hydration therapy - hypodermoclysis</p>
          </list-item>
          <list-item>
            <p>Subcutaneous urography to improve absorption of radiopaque agents&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA Approved Uses</bold>
<xref ref-type="bibr" rid="article-23060.r6">[6]</xref>
<xref ref-type="bibr" rid="article-23060.r7">[7]</xref>
<xref ref-type="bibr" rid="article-23060.r2">[2]</xref>
<xref ref-type="bibr" rid="article-23060.r8">[8]</xref>
<xref ref-type="bibr" rid="article-23060.r9">[9]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Extravasation of medications from intravenous lines management</p>
          </list-item>
          <list-item>
            <p>Adjunct to local anesthetic eye blocks for ophthalmic surgery</p>
          </list-item>
          <list-item>
            <p>Keloid scar treatment &#x02013; involves cryosurgery followed by injections with hyaluronidase, triamcinolone, and 5-fluorouracil</p>
          </list-item>
          <list-item>
            <p>Reversing cosmetic facial fillers composed of hyaluronic acid</p>
          </list-item>
        </list>
        <p>Hyaluronidase is an enzyme that degrades the glycosaminoglycan hyaluronan, more commonly known as hyaluronic acid. Hyaluronic acid is a component of the extracellular matrix that absorbs water and has a gel-like consistency.<xref ref-type="bibr" rid="article-23060.r3">[3]</xref>&#x000a0;The structure of hyaluronic acid impedes fluid movement&#x000a0;and reduces the volume of injectable drugs into the subcutaneous space. Hyaluronidase is a natural enzyme that catalyzes the degradation of hyaluronic acid through depolymerization.<xref ref-type="bibr" rid="article-23060.r3">[3]</xref></p>
        <p>Recombinant human hyaluronidase (rHuPH20) formulations are available for&#x000a0;therapeutic administration through subcutaneous injections.<xref ref-type="bibr" rid="article-23060.r1">[1]</xref><xref ref-type="bibr" rid="article-23060.r8">[8]</xref> When this enzyme is co-administered with other biotherapeutics such as insulin, immunoglobulins, or chemotherapy agents, it increases the target drug bioavailability by breaking down hyaluronic acid in the interstitial space and allowing dispersion of the medication.<xref ref-type="bibr" rid="article-23060.r1">[1]</xref>&#x000a0;The time to reach C<italic toggle="yes">max</italic> decreases when hyaluronidase is co-administered with the target&#x000a0;drug, which means that the medication&#x000a0;is better absorbed and enters systemic circulation at a faster rate with the aid of hyaluronic acid degradation.<xref ref-type="bibr" rid="article-23060.r1">[1]</xref>&#x000a0;Recombinant human hyaluronidase (rHuPH20) has been used to increase the volume of infusion, reduce the frequency of infusions, and decrease the number of infusion sites of injectable pharmaceuticals.<xref ref-type="bibr" rid="article-23060.r3">[3]</xref></p>
      </sec>
      <sec id="article-23060.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Hyaluronic acid is a glycosaminoglycan that contributes to the extracellular matrix of connective tissues. It is a large, viscous, and hygroscopic molecule that blocks the flow of fluids entering the vasculature from a subcutaneous space.<xref ref-type="bibr" rid="article-23060.r3">[3]</xref>&#x000a0;Hyaluronic acid is a linear polymer made of thousands of simple disaccharides stacked on one another, contributing to the molecule's hydrophilic properties.<xref ref-type="bibr" rid="article-23060.r10">[10]</xref><xref ref-type="bibr" rid="article-23060.r2">[2]</xref>&#x000a0;Hyaluronic acid has a relatively short half-life of 15 to 20 hours. Hyaluronidase is an enzyme that temporarily and reversibly depolymerizes hyaluronic acid; this creates microchannels in the interstitial matrix that allows fluids to flow through. Recombinant human hyaluronidase is specific for cleaving the beta 1-4 linkage of the glycosaminoglycan.<xref ref-type="bibr" rid="article-23060.r3">[3]</xref></p>
      </sec>
      <sec id="article-23060.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Typical administration of hyaluronidase is via subcutaneous injection with doses ranging from 50 to 300 units/mL.<xref ref-type="bibr" rid="article-23060.r3">[3]</xref> When using this enzyme to enhance the dispersion of another pharmaceutical agent, the administration is possible in one of two ways. It may be injected first into the subcutaneous tissue, and then the second agent may be injected sequentially with the same needle. Or it may be co-administered with the other agent in a single injection.<xref ref-type="bibr" rid="article-23060.r1">[1]</xref>&#x000a0;Studies have been conducted injecting pegylated recombinant human hyaluronidase (PEGPH20) directly into a tumor, attempting to degrade the local hyaluronic acid and improve cytotoxic agent delivery.<xref ref-type="bibr" rid="article-23060.r8">[8]</xref></p>
      </sec>
      <sec id="article-23060.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most frequently encountered adverse effects are injection site reaction, headache, fatigue, nausea, and fever. Severe reactions can include hypersensitivity reactions, anaphylaxis, hyperviscosity, and thromboembolism. Recombinant human hyaluronidase comes with a black box warning of thrombosis. Risk factors for precipitating thrombosis are hypercoagulable conditions, prolonged immobilization, advanced age, and cardiovascular disease. It is essential to hydrate adequately before administering the dose to prevent these adverse reactions.</p>
        <p>Animal-derived hyaluronidase is immunogenic and may cause allergic reactions. Human recombinant hyaluronidase (rHuPH20) is better tolerated and is less likely to cause an allergic reaction. Approximately 6% of the population have anti-rHuPH20 antibodies that are non-neutralizing and have no clinically significant consequences.<xref ref-type="bibr" rid="article-23060.r3">[3]</xref></p>
        <p>There is insufficient data available to assess fetal risk in pregnancy, nor is there&#x000a0;human data available to evaluate the effects on milk production in lactating mothers. It is essential to weigh the risks versus benefits when prescribing to pregnant or breastfeeding women.</p>
      </sec>
      <sec id="article-23060.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to this medication include hypersensitivity to this drug class or components of the injection. Caution is necessary when administering this drug to someone who is at increased risk for thrombosis.</p>
      </sec>
      <sec id="article-23060.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>It is essential to document location and monitor the injection site for acute changes. Recommendations also include monitoring renal function and vital signs during the infusion.</p>
      </sec>
      <sec id="article-23060.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity due to hyaluronidase is rare. If the enzyme gets injected intravenously, it immediately degrades, and enzymatic activity halts. Tissue inflammation may result from local hyaluronidase toxicity.<xref ref-type="bibr" rid="article-23060.r11">[11]</xref>&#x000a0;The most feared complications of hyaluronidase therapy are thrombosis or a hypersensitivity reaction; immediately discontinue the medication if either one of these&#x000a0;occurs.&#x000a0;</p>
      </sec>
      <sec id="article-23060.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Prescribing clinicians should recognize the benefit of using hyaluronidase in certain medical conditions. They should collaborate with the pharmacist to achieve an appropriate dose and method of administration. It is essential that hyaluronidase is administered by a medical professional and that patients undergo monitoring for serious complications. Patients must be adequately hydrated before dosage administration and monitored for signs of thrombosis, anaphylaxis, and injection site reaction. If hyaluronidase use is in the inpatient setting, the nursing staff monitors patient vital signs and assesses any acute changes.</p>
        <p>When using hyaluronidase for labeled indications, health care providers should know that it is&#x000a0;ineffective to deliver the medication intravenously. This enzyme rapidly degrades in the bloodstream, and the beneficial effects terminate. Also, the person administering the subcutaneous injection (typically nursing) should examine the injection site and note that it is clear of any infections. The administration of hyaluronidase in inflamed or infected tissues could precipitate the spread of the local infection.</p>
        <p>Communication is key between the patient and all healthcare providers, working as part of an interprofessional medical team. Nurses should note any changes in the patient's health status and notify the attending physician. Nursing will also almost always have the task of administering the medications. The patient should also receive instruction on drug delivery methods and possible adverse reactions should they be able to administer self-injections at home.</p>
        <p>The adjuvant therapy of adding hyaluronidase with injectable medications has improved the efficacy of many treatments. Pharmacists should consult with the prescribing/ordering clinician regarding potential dose adjustments and perform their usual function of checking doses and performing medication reconciliation. Patients require smaller dosages of their medications and can&#x000a0;receive less frequent injections due to better systemic absorption, contributing to overall improved patient compliance and satisfaction with treatment.<xref ref-type="bibr" rid="article-23060.r1">[1]</xref>&#x000a0;But as can be seen above, an interprofessional approach involving the clinicians, nursing staff, and pharmacist are necessary to optimize the use of hyaluronidase and achieve optimal results. [Level 5]</p>
      </sec>
      <sec id="article-23060.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23060&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23060">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23060/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23060">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23060.s11">
        <title>References</title>
        <ref id="article-23060.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bittner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.</article-title>
            <source>BioDrugs</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>425</fpage>
            <page-range>425-440</page-range>
            <pub-id pub-id-type="pmid">30043229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23060.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Niazi</surname>
                <given-names>ZR</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>FU</given-names>
              </name>
              <name>
                <surname>Akhtar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baloch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hyaluronidases: A Therapeutic Enzyme.</article-title>
            <source>Protein Pept Lett</source>
            <year>2018</year>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>663</fpage>
            <page-range>663-676</page-range>
            <pub-id pub-id-type="pmid">29956608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23060.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wasserman</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.</article-title>
            <source>Immunotherapy</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>12</issue>
            <fpage>1035</fpage>
            <page-range>1035-1050</page-range>
            <pub-id pub-id-type="pmid">28871852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23060.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Horton</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Coveler</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Hingorani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).</article-title>
            <source>Curr Oncol Rep</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>47</fpage>
            <pub-id pub-id-type="pmid">28589527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23060.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spandorfer</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Mace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Spiro</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Friend</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harb</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lebel</surname>
                <given-names>F</given-names>
              </name>
              <collab>Increased Flow Utilizing Subcutaneously-Enabled Pediatric Rehydration II (INFUSE-Peds II) Study Group</collab>
            </person-group>
            <article-title>A randomized clinical trial of recombinant human hyaluronidase-facilitated subcutaneous versus intravenous rehydration in mild to moderately dehydrated children in the emergency department.</article-title>
            <source>Clin Ther</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>11</issue>
            <fpage>2232</fpage>
            <page-range>2232-45</page-range>
            <pub-id pub-id-type="pmid">23062548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23060.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corbett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Harden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oddie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Treating extravasation injuries in infants and young children: a scoping review and survey of UK NHS practice.</article-title>
            <source>BMC Pediatr</source>
            <year>2019</year>
            <month>Jan</month>
            <day>07</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <pub-id pub-id-type="pmid">30616600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23060.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>R&#x000fc;schen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aravinth</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bunce</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bokre</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Use of hyaluronidase as an adjunct to local anaesthetic eye blocks to reduce intraoperative pain in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Mar</month>
            <day>02</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD010368</fpage>
            <pub-id pub-id-type="pmid">29498413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23060.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eisert</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nast</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment of extensive, recalcitrant keloids using a combination of intralesional cryosurgery, triamcinolone, 5-fluorouracil and hyaluronidase.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>735</fpage>
            <page-range>735-737</page-range>
            <pub-id pub-id-type="pmid">31131981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23060.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juh&#x000e1;sz</surname>
                <given-names>MLW</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Marmur</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>The Kinetics of Reversible Hyaluronic Acid Filler Injection Treated With Hyaluronidase.</article-title>
            <source>Dermatol Surg</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>841</fpage>
            <page-range>841-847</page-range>
            <pub-id pub-id-type="pmid">28498207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23060.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maytin</surname>
                <given-names>EV</given-names>
              </name>
            </person-group>
            <article-title>Hyaluronan: More than just a wrinkle filler.</article-title>
            <source>Glycobiology</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>553</fpage>
            <page-range>553-9</page-range>
            <pub-id pub-id-type="pmid">26964566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23060.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zamora-Alejo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leatherbarrow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lake</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Selva</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goggin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hyaluronidase toxicity: a possible cause of postoperative periorbital inflammation.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>122</fpage>
            <page-range>122-6</page-range>
            <pub-id pub-id-type="pmid">22712486</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
